In vitro sequence-dependent synergistic effect of suramin and camptothecin

Berenbaum, 1989, What is synergy?, Pharmacol Rev, 41, 93 LaRocca, 1990, Suramin: prototype of a new generation of antitumor compounds, Cancer Cells, 2, 106 Taylor, 1992, Effects of suramin on in vitro growth of fresh human tumors, J Natl Cancer Inst, 84, 489, 10.1093/jnci/84.7.489 Vignon, 1992, Inhibition of breast cancer growth by suramin, J Natl Cancer Inst, 84, 38, 10.1093/jnci/84.1.38 Bojanowski, 1992, Suramin is an inhibitor of DNA topoisomerase II in vitro in Chinese hamster fibrosarcoma cells, 89, 3025 Liu, 1989, DNA topoisomerase poisons as antitumor drugs, Annu Rev Biochem, 58, 351, 10.1146/annurev.bi.58.070189.002031 Stein, 1989, Suramin: an anticancer drug with a unique mechanism of action, J Clin Oncol, 7, 499, 10.1200/JCO.1989.7.4.499 Motzer, 1992, Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression, Cancer Res, 52, 5775 van Rijswijk, 1992, Suramin: rapid loading and weekly maintenance regimens for cancer patients, J Clin Oncol, 10, 1, 10.1200/JCO.1992.10.11.1788 Horwitz, 1971, Studies on camptothecin: I. Effects on nucleic acid and protein synthesis, Mol Pharmacol, 7, 632 Slichenmyer, 1993, The current status of camptothecin analogues as antitumor agents, J Natl Cancer Inst, 85, 271, 10.1093/jnci/85.4.271 Tsuruo, 1988, Anti-tumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumours in vitro, Cancer Chemother Pharmacol, 21, 71, 10.1007/BF00262744 Kaufmann, 1991, Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line, Cancer Res, 51, 1129 D'Arpa, 1990, Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons, Cancer Res, 50, 6919 Bertrand, 1992, Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells, Eur J Cancer, 28A, 743, 10.1016/0959-8049(92)90107-D Eisenberger, 1992, Suramin, an active nonhormonal cytotoxic drug for treatment of prostate cancer: compelling reasons for testing in patients with hormone-refractory breast cancer, J Natl Cancer Inst, 84, 3, 10.1093/jnci/84.1.3 Skehan, 1990, New colorimetric cytotoxicity assay for anticancer-drug screening, J Natl Cancer Inst, 82, 1113, 10.1093/jnci/82.13.1107 Keepers, 1991, Comparison of the sulforhodamine B protein and the tetrazolium (MTT) assays for in vitro chemosensitivity testing, Eur J Cancer, 27, 897, 10.1016/0277-5379(91)90142-Z Chou, 1983, Quantitative analysis of dose-effect relationship: the combined effects of multiple drugs on enzyme inhibitors, 27 Davis, 1983, New Methods in Molecular Biology, 27 Tsai-Pflugfelder, 1988, Cloning and sequencing of DNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22, 85, 7177 Juan, 1988, Human DNA topoisomerase I is encoded by a single-copy gene that maps to chromosome region 20q12-13.2, 85, 8910 Fort, 1985, Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigenic family, Nucleic Acids Res, 13, 1431, 10.1093/nar/13.5.1431 Lopez-Lopez, 1992, The effect of schedule, protein binding and growth factors on the activity of suramin, Int J Cancer, 51, 921, 10.1002/ijc.2910510615 Myers, 1992, Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer, J Clin Oncol, 10, 881, 10.1200/JCO.1992.10.6.881 Fruehauf, 1990, Synergistic activity of suramin with tumor necrosis factor α and doxorubicin on human prostate cancer cell lines, J Natl Cancer Inst, 82, 1206, 10.1093/jnci/82.14.1206 Stein, 1993, Suramin: a novel antineoplastic agent with multiple potential mechanisms of action, Cancer Res, 53, 2239 Li, 1972, Action of camptothecin on mammalian cells in culture, Cancer Res, 32, 2643 Karato, 1993, Phase I study of CPT-II and etoposide in patients with refractory solid tumors, J Clin Oncol, 11, 2030, 10.1200/JCO.1993.11.10.2030 Anzai, 1992, Synergistic cytotoxicity with 2′-deoxy-5-azacytidine and topotecan in vitro and in vivo, Cancer Res, 52, 2180